CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, today announced that following a planned safety review by an independent Data Safety Monitoring Board (DSMB) of its pivotal trial of romidepsin as a treatment for patients with cutaneous T-cell lymphoma (CTCL), the DSMB recommended that Gloucester continue the trial without any modifications. The DSMB had the same recommendation in each of three previous separate review meetings held in 2006.
